Atinary intends to integrate Chemspeed configurable laboratory automation platforms, Bruker analytical instruments and SciY scientific software into its agentic AI workflows. Bruker acquired ...
Although biotech start-ups stand out with their mega-investments, there are numerous successful start-ups in the life sciences sector centred around pharmaceuticals.
Technologie, KI und die digitale Zukunft des Standorts Basel: Nach dem erfolgreichen Auftakt im Juni 2026 mit über 100 Teilnehmenden und einer beeindruckenden Resonanz findet nun die zweite Ausgabe ...
Das 2020 gegründete Zürcher Unternehmen Circet Schweiz übernimmt Technik Partner, einen Spezialisten für die ...
Aisot Technologies AG, das ETH-Zürich-Spin-off für KI-gestützte Portfolio-Intelligenz für institutionelle Investoren, hat eine Seed-Extension-Finanzierungsrunde über CHF 2 Millionen erfolgreich ...
Oculis is a biopharmaceutical company focused on neuro-ophthalmology and ophthalmology. Its late-stage clinical pipeline focuses on two core product candidates. Privosegtor and Licaminlimab.
FGE NexantECA has completed the acquisition of Morges-based Square Commodities ("SquareCo"), the leading research and data analytics platform specialising in the global renewable fuels market. Founded ...
The shareholders of Swiss sovereign cloud provider Infomaniak have signed an agreement for the listing of the company on the SIX Swiss Exchange, through a reverse takeover transaction with Perrot ...
Vaud-based PeriVision, a University of Bern spin-off, has developed VisionOne, a platform that uses virtual reality glasses to measure the impact of glaucoma on visual fields – information that is ...
Zerolook builds a B2B flight pricing API for OTAs and airlines that predicts itinerary prices directly with machine learning, instead of running a live search every time a price is needed. The ...
Ensysce Biosciences, a clinical-stage company developing a new class of highly novel opioids for the treatment of severe pain, has acquired Zug-based Cy Biopharma, a clinical-stage biotechnology ...
Basel-based Vaderis Therapeutics, a clinical-stage biopharmaceutical company focused on developing targeted therapies for rare vascular diseases, today announced the closing of a private $152 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results